Adjuvant tamoxifen adherence in male patients with breast cancer: An ongoing challenge

Male breast cancer, a rare disease, is usually treated with adjuvant tamoxifen during early stages. Unfortunately, studies suggest a high rate of discontinuing adjuvant tamoxifen, but reasons for stopping this treatment are not always clear, and additional studies investigating this are needed.

Saved in:

Bibliographic Details
Published in	Cancer Vol. 128; no. 1; pp. 22 - 24
Main Author	Falkson, Carla I.
Format	Journal Article
Language	English
Published	United States Wiley Subscription Services, Inc 01.01.2022
Subjects	adjuvant endocrine therapy adjuvant tamoxifen Antineoplastic Agents, Hormonal - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms, Male - drug therapy discontinuing treatment drug adherence Humans Longitudinal Studies Male male breast cancer Males Mens health Tamoxifen Tamoxifen - therapeutic use male breast cancer adjuvant endocrine therapy adjuvant tamoxifen drug adherence discontinuing treatment
Online Access	Get full text
ISSN	0008-543X 1097-0142 1097-0142
DOI	10.1002/cncr.33898

Cover

More Information
Summary:	Male breast cancer, a rare disease, is usually treated with adjuvant tamoxifen during early stages. Unfortunately, studies suggest a high rate of discontinuing adjuvant tamoxifen, but reasons for stopping this treatment are not always clear, and additional studies investigating this are needed.
Bibliography:	See referenced original article on pages this issue. 59‐64 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Editorial-2 ObjectType-Commentary-1 content type line 23
ISSN:	0008-543X 1097-0142 1097-0142
DOI:	10.1002/cncr.33898